絞り込み

16646

広告

東北電力 女川原発2号機 地元自治体が再稼働をどう判断か注目 (NHK)

26日、原子力規制委員会の審査に合格した宮城県にある女川原子力発電所2号機について国と東北電力は、再稼働に必要な自治体の同意に向けた手続きを進めることになり今後...

  1. 無観客ライブを無料配信 会場費などはファ...
  2. 突然の異常行動を伴う頭痛、疑うべき疾患は...
  3. COVID-19の拡大で重み増す保健所長...
  4. SARS-CoV-2が眼から感染する可能...

ニュース一覧

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

著者 Biver E , Calmy A , Aubry-Rozier B , Birkhäuser M , Bischoff-Ferrari HA , Ferrari S , Frey D , Kressig RW , Lamy O , Lippuner K , Suhm N , Meier C
Osteoporos Int.2019 Jan 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (11view , 0users)

Full Text Sources

Medical

Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general population. Accordingly, age-related comorbidities, including osteoporosis, are increasing. Fracture risk is higher and increases approximately 10 years earlier in PLWH. Classical risk factors of bone fragility are highly prevalent in PLWH but factors specific for HIV infection itself and the type of antiretroviral therapy (ART) (triple combination antiretroviral therapy) regimen (especially tenofovir and protease inhibitors) also contribute to bone loss. The majority of bone loss occurs during virus activity and at initiation of ART (immune reconstitution) and is associated with an increase of bone resorption (upregulation RANKL). Recent data indicate that calcium and vitamin D supplements as ART initiation lower BMD loss. The reduction of tenofovir plasma concentrations with tenofovir alafenamide attenuates BMD loss but it remains unknown whether it will contribute to reduce fracture risk. Hence, special considerations for the management of bone fragility in PLWH are warranted. Based on the current state of epidemiology and pathophysiology of osteoporosis in PLWH, we provide the consensus of the Swiss Association against Osteoporosis on best practice for diagnosis, prevention, and management of osteoporosis in this population. Periodic assessment of fracture risk is indicated in all HIV patients and general preventive measures should be implemented. All postmenopausal women, men above 50 years of age, and patients with other clinical risk for fragility fractures qualify for BMD measurement. An algorithm clarifies when treatment with bisphosphonates and review of ART regimen in favour of more bone-friendly options are indicated.
PMID: 30603840 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード